Scholarlink

Purpose <p>To evaluate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) for residual dizziness (RD) after benign paroxysmal positional vertigo (BPPV) repositioning.</p> Methods <p>This retrospective study included 170 patients with RD after BPPV repositioning, allocated to ginkgo biloba extract (GBE, <i>n</i> = 63), vestibular rehabilitation therapy(VRT, <i>n </i>= 65, VRT + GBE), or rTMS (<i>n </i>= 42, rTMS + GBE) groups, according to the treatment received. Dizziness Handicap Inventory (DHI) and Visual Analog Scale (VAS) scores were assessed at multiple time points. Psychological status, quality of life, clinical efficacy, recurrence, and safety were also evaluated.</p> Results <p>DHI and VAS scores reductions were greater in rTMS and VRT groups than GBE alone at all time points (<i>P </i>&lt; 0.05), with rTMS showing greater short-term DHI improvement and better SDS reduction than VRT (<i>P</i> &lt; 0.05). SF-36 scores improved more in rTMS and VRT groups. Efficacy rates were 97.62% (rTMS), 100% (VRT), and 96.83% (GBE) (<i>P </i>&lt; 0.05).</p> Conclusion <p>rTMS combined with GBE was associated with short-term symptom and depressive improvement in RD patients. Due to non-randomized design, findings require confirmation in prospective trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of clinical efficacy of repetitive transcranial magnetic stimulation in the treatment of residual dizziness after reduction of benign paroxysmal positional vertigo

  • 期刊论文

  • 发表日期：

    2026年4月30日

查看全文
  • Feng Luan,
  • Xin-Yu Wang,
  • Jun-Jie Xing,
  • Yu Zhang,
  • Zhan-Chi Zhang

摘要

Purpose

To evaluate the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) for residual dizziness (RD) after benign paroxysmal positional vertigo (BPPV) repositioning.

Methods

This retrospective study included 170 patients with RD after BPPV repositioning, allocated to ginkgo biloba extract (GBE, n = 63), vestibular rehabilitation therapy(VRT, n = 65, VRT + GBE), or rTMS (n = 42, rTMS + GBE) groups, according to the treatment received. Dizziness Handicap Inventory (DHI) and Visual Analog Scale (VAS) scores were assessed at multiple time points. Psychological status, quality of life, clinical efficacy, recurrence, and safety were also evaluated.

Results

DHI and VAS scores reductions were greater in rTMS and VRT groups than GBE alone at all time points (P < 0.05), with rTMS showing greater short-term DHI improvement and better SDS reduction than VRT (P < 0.05). SF-36 scores improved more in rTMS and VRT groups. Efficacy rates were 97.62% (rTMS), 100% (VRT), and 96.83% (GBE) (P < 0.05).

Conclusion

rTMS combined with GBE was associated with short-term symptom and depressive improvement in RD patients. Due to non-randomized design, findings require confirmation in prospective trials.